A California CLIA Lab operator faces legal repercussions for deceptive marketing practices in allergy testing, violating EKRA by targeting non-specialists for profit.
Recent court rulings reshape reproductive health care privacy and regulations, emphasizing the need for updated HIPAA policies and awareness of state laws.
Practices must prepare for stricter fraud reporting and compliance as the DOJ Corporate Whistleblower Awards Pilot Program and bipartisan AI Whistleblower Protection Act expand protections beyond the False Claims Act.
Practice administrators seeking federal grants or contracts must look beyond HIPAA, completing SAM registration and adopting FAR 52.204‑21’s 15 essential cybersecurity controls to safeguard PHI, PII, FCI and CUI.